MIRA Pharmaceuticals, Inc. Deferred Costs, Current
MIRA Pharmaceuticals, Inc. (MIRA) had Deferred Costs, Current of $353.37 thousand as of 2023-06-30, per its 10-Q filed 2023-09-15.
Discontinued › Balance Sheet › Assets › Deferred Costs, Current
us-gaap:DeferredCostsCurrent · last filed 2024-04-01
- 2023-06-30: Deferred Costs, Current $353.37K.
- 2022-12-31: Deferred Costs, Current $143.43K.
| Period end | Deferred Costs, Current |
|---|---|
| 2023-06-30 | $353.37K 10-Q · filed 2023-09-15 |
| 2022-12-31 | $143.43K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |